Erratum: Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials (Diabetologia DOI: 10.1007/s00125-012-2653-7);Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials

Diabetologia

Volumn 55, Issue 10, 2012, Pages 2593-2603

  Stevens, R J ^a   Ali, R ^b   Bankhead, C R ^a   Bethel, M A ^b   Cairns, B J ^b   Camisasca, R P ^c   Crowe, F L ^b   Farmer, A J ^a   Harrison, S ^a   Hirst, J A ^a   Home, P ^d   Kahn, S E ^e   McLellan, J H ^a   Perera, R ^a   Pluddemann A ^a   Ramachandran, A ^f   Roberts, N W ^a   Rose, P W ^a   Schweizer, A ^g   Viberti, G ^h   Holman, R R ^b   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Takeda Pharmaceutical Company   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Dr A Ramachandran's Diabetes Hospitals   (India)

^g NOVARTIS PHARMA AG   (Switzerland)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Meta analysis; Metformin; Neoplasms; Systematic review

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; GLIBENCLAMIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; DIABETES MELLITUS; FOLLOW UP; HUMAN; LIFESTYLE MODIFICATION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84866138849     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2740-9     Document Type: Erratum

References (47)

1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167 (Pubitemid 38747263)
2. Seshasai SRK, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829-841
3. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305 (Pubitemid 40813563)
4. Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
5. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
6. Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631-1637
7. Landman GWD, Kleefstra N, van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG (2010) Metformin associated with lower cancer mortality in type 2 diabetes: Zodiac-16. Diabetes Care 33:322-326
8. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11:20
9. Ruiter R, Visser LE, van Herk-Sukel MPP et al (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35:119-124
10. DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451-1461
11. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7:e33411
12. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299-304
13. Chen G, Xu S, Renko K, Derwahl M (2012) Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 97:E510-E520
14. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q (2011) Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58:482-490
15. Bao B, Wang Z, Ali S et al (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5:355-364
16. Arkadieva AV, Mamonov AA, Popovich IG, Anisimov VN, Mikhelson VM, Spivak IM (2011) Metformin slows down ageing processes at the cellular level in SHR mice. Cell Tissue Biol 5:151-159
17. Anisimov VN, Berstein LM, Popovich IG et al (2011) If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging 3:148-157
18. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865 (Pubitemid 28416719)
19. Knowler WC, Barrett-Connor E, Fowler SE et al, Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403 (Pubitemid 34437694)
20. Moghetti P, Castello R, Negri C et al (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146 (Pubitemid 32268804)
21. Lefebvre C, Manheimer E, Glanville J (2011) Chapter 6: Searching for studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.Cochrane-handbook.org
22. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, Art. no: CD002967, doi 10.1002/14651858.CD002967.pub4
23. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301-1309
24. StataCorp. (2009) Stata statistical software: release 11.
25. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J (2008) metan: fixed- and random-effects meta-analysis. Stata Journal 8:3-28
26. Yusuf S, Peto R, Lewis J (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371 (Pubitemid 15107153)
27. Higgins JPT, Altman DG, Sterne JAC (2008) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.Cochrane-handbook.org
28. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135
29. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV (2005) Comparative outcomes study of metformin intervention versus conventional approach: the COSMIC Approach Study. Diabetes Care 28:539-543 (Pubitemid 40315310)
30. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297 (Pubitemid 43185397)
31. Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R (2011) Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 13:567-576
32. Kahn SE, Haffner SM, Heise MA et al, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443 (Pubitemid 44903747)
33. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838-1845
34. Turner RC, Holman RR (1999) Metformin and risk of cardiovascular disease. Cardiology 91:203-204 (Pubitemid 29454259)
35. Lawlor DA, Smith GD, Kundu D, Bruckdorfer KR, Ebrahim S (2004) Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet 363:1724-1727 (Pubitemid 38670332)
36. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:25-31
37. Ferrara A, Lewis JD, Quesenberry CP Jr et al (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34:923-929
38. Monami M, Lamanna C, Marchionni N, Mannucci E (2008) Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31:1455-1460
39. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506
40. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 281:2005-2012 (Pubitemid 29254858)
41. Schneider MB, Matsuzaki H, Haorah J et al (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263-1270 (Pubitemid 32246678)
42. Muti P, Berrino F, Krogh V et al (2009) Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle 8:2661
43. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V (2003) Six-year results from the Early Diabetes Intervention Trial. Diabetic Medicine 20:15, Abstract
44. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076 (Pubitemid 39628416)
45. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147 (Pubitemid 38196723)
46. Schweizer A, Couturier A, Foley JE, Dejager S (2007) Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24:955-961 (Pubitemid 47301637)
47. Williams-Herman D, Johnson J, Teng R et al (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 12:442-451